The Silk flow-diverter stent for endovascular treatment of intracranial aneurysms

Alghamdi, Faisal; Morais, Ricardo; Scillia, Pietro; Lubicz, Boris

doi:10.1586/17434440.2015.1093413

Cited by 15 publications

(5 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the treatments for intracranial aneurysms is the use of silk in the form of a silk flow-diverter stent (Alghamdi et al, 2015), which allows complete occlusion 1 year after treatment in most cases, making them an effective treatment tool (Alghamdi et al, 2015;Leonardi et al, 2011).…”

Section: Intra Cranial Aneurysmsmentioning

confidence: 99%

Biomedical applications of silkworm ( Bombyx Mori ) proteins in regenerative medicine (a narrative review)

Khosropanah

Vaghasloo

Shakibaei

et al. 2021

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Silk worm (Bombyx Mori) protein, have been considered as potential materials for a variety of advanced engineering and biomedical applications for decades. Recently, silkworm silk has gained significant importance in research attention mainly because of its remarkable and exceptional mechanical properties. Silk has already been shown to have unique interactions with cells in tissues through bio-recognition units. The natural silk contains fibroin and sericin and has been used in various tissues of the human body (skin, bone, nerve, and so on). Besides, silk also still has anti-cancer, anti-tyrosinase, anti-coagulant, anti-oxidant, anti-bacterial, and antidiabetic properties. This article is supposed to describe the diverse biomedical capabilities of B. Mori silk as the appropriate biomaterial among the assorted natural and artificial polymers that are presently accessible, and ideal for usage in regenerative medicine fields.

show abstract

Section: Intra Cranial Aneurysmsmentioning

confidence: 99%

Biomedical applications of silkworm ( Bombyx Mori ) proteins in regenerative medicine (a narrative review)

Khosropanah

Vaghasloo

Shakibaei

et al. 2021

J Tissue Eng Regen Med

View full text Add to dashboard Cite

show abstract

“…Literature search was performed on March 21, 2022. After removal of duplicates and screening of titles and abstracts, we sought for the original articles of 82 publications 7 13–93. After completion of literature review and data extraction and before closing the database, the literature search was repeated on PubMed only on May 22, 2022, using the above-mentioned search string to identify additional potentially eligible articles.…”

Section: Resultsmentioning

confidence: 99%

Flow diversion for compressive unruptured internal carotid artery aneurysms with neuro-ophthalmological symptoms: a systematic review and meta-analysis

Kaiser

Cuberi

Linn

et al. 2022

J NeuroIntervent Surg

View full text Add to dashboard Cite

BackgroundData on the safety and efficacy of flow diverters (FD) for the treatment of unruptured internal carotid artery (ICA) aneurysms with compressive neuro-ophthalmological symptoms (NOS) are scarce and comprise mainly small case series.MethodsWe performed a search of three databases and included series with ≥10 patients, with unruptured aneurysms of the ICA and NOS, treated with FD. Random-effects analysis of treatment results and safety was performed.ResultsA total of 22 studies reporting on 594 patients were included. Pooled proportions of NOS recovery, improvement, transient and permanent worsening were: 47.4% (95% CI 35.0% to 60.1%); 74.5% (95% CI 67.9% to 80.2%); 7.1% (95% CI 3.3% to 14.7%); and 4.9% (95% CI 3.2% to 7.4%), respectively. Rates of complete recovery and improvement in patients with isolated visual symptoms were 30.6% (95% CI 12.5% to 57.7%) and 56.6% (95% CI 42.3% to 69.9%). Isolated oculomotor symptoms recovered completely in 47.8% (95% CI 29.9% to 66.3%) and improved in 78% (95% CI 69.2% to 84.9%). Morbidity occurred in 5% (95% CI 2.8% to 9%) and mortality in 3.9% (95% CI 2% to 7.5%) of patients. An increased likelihood of symptom improvement was observed when treatment was performed early (<1 month) after symptom onset (OR=11.22, 95% CI 3.9% to 32.5%).ConclusionFlow diversion promotes recovery or improvement of compressive symptoms in a large proportion of patients but is associated with significant rates of morbidity and mortality. Transient and permanent NOS worsening is not uncommon. Early treatment is of utmost importance, as it increases the likelihood of symptom improvement more than 10-fold.

show abstract

“…A newgeneration Silkϩ device has flared ends, lower porosity, higher radial force, greater slide capacity, an extrasupple and shorter (9 mm) distal radiopaque tip, and 8 platinum markers ( Fig 2). 42 Like its predecessor, the Silkϩ device requires a smaller delivery microcatheter than other similar endovascular devices, 0.023 inches, though like others, it uses a 6F or 7F guide catheter. 4 Tapered options are available for use in irregular anatomies.…”

Section: Conventional Braided Mesh Devicesmentioning

confidence: 99%

On Flow Diversion: The Changing Landscape of Intracerebral Aneurysm Management

Dmytriw

Phan

Moore

et al. 2019

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

Uptake of flow-diverting technology is rapidly outpacing the availability of clinical evidence. Most current usage is off-label, and the endovascular community is nearer the beginning than the end of the learning curve, given the number of devices in development. A comprehensive overview of technical specifications alongside key outcome data is essential both for clinical decision-making and to direct further investigations. Most-studied has been the Pipeline Embolization Device, which has undergone a transition to the Pipeline Flex for which outcome data are sparse or heterogeneous. Alternative endoluminal devices do not appear to be outperforming the Pipeline Embolization Device to date, though prospective studies and long-term data mostly are lacking, and between-study comparisons must be treated with caution. Nominal technical specifications may be unrelated to in situ performance, emphasizing the importance of correct radiologic sizing and device placement. Devices designed specifically for bifurcation aneurysms also lack long-term outcome data or have only recently become available for clinical use. There are no major studies directly comparing a flow-diverting device with standard coiling or microsurgical clipping. Data on flow-diverting stents are too limited in terms of long-term outcomes to reliably inform clinical decision-making. The best available evidence supports using a single endoluminal device for most indications. Recommendations on the suitability and choice of a device for bifurcation or ruptured aneurysms or for anatomically complex lesions cannot be made on the basis of current evidence. The appropriateness of flow-diverting treatment must be decided on a case-by-case basis, considering experience and the relative risks against standard approaches or observation. ABBREVIATION: MCR ϭ metal coverage ratio T he Pipeline Embolization Device (PED; Covidien, Irvine, California) was approved by the FDA in 2011 and by the European Medicines Agency (EMA) in 2008 for the treatment of large or giant, wide-neck intracranial aneurysms of the internal carotid artery from the petrous to the superior hypophyseal segments. 1 Currently, this is the only device approved in the United States. In Europe, there are additional options, including the PED,

show abstract

The Silk flow-diverter stent for endovascular treatment of intracranial aneurysms

Cited by 15 publications

References 94 publications

Biomedical applications of silkworm ( Bombyx Mori ) proteins in regenerative medicine (a narrative review)

Biomedical applications of silkworm ( Bombyx Mori ) proteins in regenerative medicine (a narrative review)

Flow diversion for compressive unruptured internal carotid artery aneurysms with neuro-ophthalmological symptoms: a systematic review and meta-analysis

On Flow Diversion: The Changing Landscape of Intracerebral Aneurysm Management

Contact Info

Product

Resources

About